Key result
The ASFV-ΔECM3 vaccine candidate provided 100% protection against homologous challenge with the virulent parental GZ201801 virus in pigs, compared to 0% survival in the non-immunized group.
Why the study?
There are no safe or commercially available vaccines for African swine fever virus, and attenuated vaccines raise safety concerns despite their effectiveness.
Does the ASFV-ΔECM3 live-attenuated vaccine candidate protect piglets against homologous African swine fever virus challenge?
Does the ASFV-ΔECM3 live-attenuated vaccine candidate protect piglets against homologous African swine fever virus challenge?
Absolute Event Rate: 100% vs 0%
The five-gene-deleted ASFV-ΔECM3 virus is a safe and effective live-attenuated vaccine candidate that provides complete protection against homologous African swine fever virus challenge in pigs.
No takes yet. Share an insight, caveat, or question.
ASFV-ΔECM3 merits further vaccine development in swine; leaves open validation against heterologous strains and in commercial settings.
Xie et al. (2022) studied African Swine Fever (n=20). ASFV-ΔECM3 vaccine candidate vs. Non-immunized control / Wild-type ASFV GZ201801 was evaluated on Survival after homologous challenge. The ASFV-ΔECM3 vaccine candidate provided 100% protection against homologous challenge with the virulent parental GZ201801 virus in pigs, compared to 0% survival in the non-immunized group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: